Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients-MedSci.cn

Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Sallman, DA; Al-Homsi, AS; Davila, ML; Kerre, T; Moors, I; Poire, X; Havelange, V; Lewalle, P; Pollyea, DA; Wang, ES; Blum, W; Demoulin, B; Sotiropoulou, PA; Alcantar-Orozco, E; Breman, E; Dheur, MS; Braun, N; Lonez, C; Gilham, DE; Flament, A; Lehmann, FF

BLOOD, 2020; 136 ():

科室
- - 订阅+
  - 更多科室
工具
服务